The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...

Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...

The STOX Suite is a digital platform that standardizes the measurement of steroid-toxicity, enabling researchers and ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...

The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new ...

Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...

From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of ...